Market capitalization | $3.91b |
Enterprise Value | $3.80b |
P/E (TTM) P/E ratio | 42.08 |
EV/FCF (TTM) EV/FCF | 56.10 |
EV/Sales (TTM) EV/Sales | 10.97 |
P/S ratio (TTM) P/S ratio | 11.27 |
P/B ratio (TTM) P/B ratio | 22.02 |
Revenue growth (TTM) Revenue growth | 1,341.63% |
Revenue (TTM) Revenue | $346.73m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a TG Therapeutics, Inc. forecast:
9 Analysts have issued a TG Therapeutics, Inc. forecast:
Dec '23 | |
Current assets | 318 318 |
Fixed assets | 12 12 |
Total Assets | 330 330 |
Dec '23 | |
Equity | 161 161 |
Debt capital | 169 169 |
Total Capital | 330 330 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Weiss |
Employees | 264 |
Founded | 1993 |
Website | www.tgtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.